Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort

Archives of Internal Medicine

Volumn 160, Issue 8, 2000, Pages 1134-1140

  Erb, Peter ^a,b   Battegay, Manuel ^a   Zimmerli, Werner ^a   Rickenbach, Martin ^c   Egger, Matthias ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

EID: 0034708984     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.8.1134     Document Type: Article

References (33)

1. Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259:1749-1754.
2. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol. 1994; 32:292-300.
3. Loveday C, Hill A. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet. 1995;345:790-791.
4. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996; 272:1167-1170.
5. + lymphocyte counts and the risk ot progression to AIDS. N Engl J Med. 1996; 334:426-431.
6. Michael NL, Chang G, Kim JH, Birx DL. Dynamics of cell-free viral burden in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:237-242.
7. Farzadegan H, Henrard DR, Kleeberger CA, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:448-455.
8. Iuliano R, Forastieri G, Brizzi M, Mecocci L, Mazzotta F, Ceccherini-Nelli L. Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline. J Acquir Immune Delic Syndr Hum Retroviral. 1997;14:408-414.
9. Galetto-Lacour A, Yerly S, Perneger TV, et al. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis. 1996;173:1388-1393.
10. + cell counts in HIV-infected patients. Arch Intern Med. 1998;158:247-252.
11. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
12. Saag MS. Use of HIV viral load in clinical practice: back to the future. Ann Intern Med. 1997;126:983-985.
13. Ledergerber B, von Overbeck J, Egger M, Lüthy R, and the Swiss HIV Cohort Study. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed. 1994;39:387-394.
14. Opravil M, Rickenbach M, Ledergerber B. Die Schweizerische Kohortenstudie: Verbindung zwischen klinischer Forschung und ärztlicher Praxis. Ther Umsch. 1998;55:329-334.
15. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. AIDS. 1998;12:1195-1201.
16. Fâtkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11(suppl):F113-F116.
17. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
18. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
19. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454.
20. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194-1199.
21. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group. Lancet. 1998;352: 1725-1730.
22. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
23. d'Arminio Monforte A, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS. 1998;12:1631-1637.
24. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280:35-41.
25. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011-1017.
26. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337:725-733.
27. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
28. Bonfanti P, Capetti A, Di Mattei P, Niero F, Rizzardini G. Virological treatment failure of highly active antiretroviral therapy in an unselected cohort of HIV-infected patients (letter], AIDS. 1998;12:1111.
29. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-750.
30. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723-724.
31. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study. Lancet 1999;353:863-868.
32. Phillips AN, Smith GD, Johnson MA. Will we ever know when to treat HIV infection? BMJ. 1996;313:608-610.
33. Hirschel B, Francioli P. Progress and problems in the fight against AIDS. N Engl J Med. 1998;338:906-908.